Oral Genome has announced a partnership with Henry Schein to expand access to its point-of-care saliva testing platform through dental and medical practices across the United States.
According to the company, the collaboration is designed to support broader integration between oral and systemic health by delivering real-time biomarker analysis at the chairside. The test delivers results in approximately 15 minutes and uses a software application to assess salivary markers connected to conditions such as dental caries, periodontal disease, and diabetes.
“We’re thrilled to join forces with Henry Schein to support providers bridging the gap between dental and medical care,” said Dr. Tina Saw, CEO of Oral Genome. “Our point-of-care testing equips practitioners with actionable insights, transforming routine visits into opportunities for whole-health advocacy.”
The distribution rollout will take place through Henry Schein’s existing dental and medical channels. According to the companies, this includes outreach to dental practices, community health clinics, and medical offices interested in preventive care and systemic health screening.
“Henry Schein is committed to bringing advanced solutions that enhance patient outcomes to our customers,” said Dirk Benson, president of Henry Schein’s U.S. distribution group. “Expanded point of care testing offerings align with our mission to advance prevention and wellness through systemic health models, and Oral Genome offers dentists and physicians a powerful tool to elevate care.”
Oral Genome’s testing kits are mobile-compatible and do not require laboratory processing. According to the company, the platform is being used by health systems, dental service organizations, and state agencies, and is designed to support value-based care and improve access to prevention, particularly in underserved communities. The company has received investment support from the American Dental Association.
More information is available online at www.oralgenome.com and www.henryschein.com.